Literature DB >> 24528553

Current research on chronic active Epstein-Barr virus infection in Japan.

Shigeyoshi Fujiwara1, Hiroshi Kimura, Ken-ichi Imadome, Ayako Arai, Eiichi Kodama, Tomohiro Morio, Norio Shimizu, Hiroshi Wakiguchi.   

Abstract

Epstein-Barr virus (EBV) infection is usually asymptomatic and persists lifelong. Although EBV-infected B cells have the potential for unlimited proliferation, they are effectively removed by the virus-specific cytotoxic T cells, and EBV-associated lymphoproliferative disease develops only in immunocompromised hosts. Rarely, however, individuals without apparent immunodeficiency develop chronic EBV infection with persistent infectious mononucleosis-like symptoms. These patients have high EBV-DNA load in the peripheral blood and systemic clonal expansion of EBV-infected T cells or natural killer (NK) cells. Their prognosis is poor with life-threatening complications including hemophagocytic lymphohistiocytosis, organ failure, and malignant lymphomas. The term "chronic active EBV infection" (CAEBV) is now generally used for this disease. The geographical distribution of CAEBV is markedly uneven and most cases have been reported from Japan and other East Asian countries. Here we summarize the current understanding of CAEBV and describe the recent progress of CAEBV research in Japan.
© 2014 Japan Pediatric Society.

Entities:  

Keywords:  EBV-associated T/NK-cell lymphoproliferative disease; EBV-associated hemophagocytic lymphohistiocytosis; Epstein-Barr virus; chronic active EBV infection; flow-cytometric in situ hybridization; hydroa vacciniforme; hypersensitivity to mosquito bites; mouse model

Mesh:

Year:  2014        PMID: 24528553     DOI: 10.1111/ped.12314

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  33 in total

1.  Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.

Authors:  Ichiro Yonese; Chizuko Sakashita; Ken-Ichi Imadome; Tohru Kobayashi; Masahide Yamamoto; Akihisa Sawada; Yoshinori Ito; Noriko Fukuhara; Asao Hirose; Yusuke Takeda; Masanori Makita; Tomoyuki Endo; Shun-Ichi Kimura; Masataka Ishimura; Osamu Miura; Shouichi Ohga; Hiroshi Kimura; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2020-07-14

2.  Epstein-Barr Virus Type 2 Infects T Cells in Healthy Kenyan Children.

Authors:  Carrie B Coleman; Ibrahim I Daud; Sidney O Ogolla; Julie A Ritchie; Nicholas A Smith; Peter O Sumba; Arlene E Dent; Rosemary Rochford
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

3.  Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

Authors:  Elisabet Bergsten; AnnaCarin Horne; Maurizio Aricó; Itziar Astigarraga; R Maarten Egeler; Alexandra H Filipovich; Eiichi Ishii; Gritta Janka; Stephan Ladisch; Kai Lehmberg; Kenneth L McClain; Milen Minkov; Scott Montgomery; Vasanta Nanduri; Diego Rosso; Jan-Inge Henter
Journal:  Blood       Date:  2017-09-21       Impact factor: 22.113

4.  Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines.

Authors:  Carrie B Coleman; Eric M Wohlford; Nicholas A Smith; Christine A King; Julie A Ritchie; Paul C Baresel; Hiroshi Kimura; Rosemary Rochford
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

5.  A rare B-cell type chronic active Epstein-Barr virus infection patient mimicking lymphoma on 18F-FDG PET/CT and literature review.

Authors:  Hao Jiao; Yongbai Zhang; Zhao Chen; Xueqi Chen; Yongkang Qiu; Wenpeng Huang; Lin Nong; Lei Kang
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-08-20

Review 6.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

7.  Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.

Authors:  Carrie B Coleman; Julie Lang; Lydia A Sweet; Nicholas A Smith; Brian M Freed; Zenggang Pan; Bradley Haverkos; Roberta Pelanda; Rosemary Rochford
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

8.  Clinicopathological characteristics of four cases of EBV positive T-cell lymphoproliferative disorders of childhood in China.

Authors:  Wenting Huang; Ning Lv; Jianming Ying; Tian Qiu; Xiaoli Feng
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.

Authors:  Nicholas A Smith; Carrie B Coleman; Benjamin E Gewurz; Rosemary Rochford
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

10.  Clinical Features of Intestinal Ulcers Complicated by Epstein-Barr Virus Infection: Importance of Active Infection.

Authors:  Yuyuan Liu; Yuqin Li; Yajun Li; Shuang Wu; Xinyue Tian; Tongyu Tang; Haibo Sun; Chuan He
Journal:  Dis Markers       Date:  2021-05-03       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.